B. Mazzi

发表

Thyroglobulin autoantibodies switch to immunoglobulin (Ig)G1 and IgG3 subclasses and preserve their restricted epitope pattern after 131I treatment for Graves' hyperthyroidism: the activity of autoimmune disease influences subclass distribution but not epitope pattern of autoantibodies

P. Vitti, M. Tonacchera, P. Piaggi, 2014, Clinical and experimental immunology.

Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.

A. Pinchera, G. Ceccarini, L. Chiovato, 1999, The Journal of clinical endocrinology and metabolism.

Activating thyrotropin receptor mutations in histologically heterogeneous hyperfunctioning nodules of multinodular goiter.

A. Pinchera, G. Ceccarini, L. Chiovato, 1998, Thyroid : official journal of the American Thyroid Association.

Orbital Decompression in Graves' Ophthalmopathy by Medial and Lateral Wall Removal

M. Nardi, C. Marcocci, A. Pinchera, 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Current Medical Management of Thyroid Orbitopathy

C. Marcocci, A. Pinchera, L. Bartalena, 2005 .

Perspective Current Medical Management of Graves Ophthalmopathy

C. Marcocci, A. Pinchera, L. Bartalena, 2002 .

Current medical management of Graves ophthalmopathy.

C. Marcocci, A. Pinchera, L. Bartalena, 2002, Ophthalmic plastic and reconstructive surgery.

Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients

M. Nardi, P. Vitti, R. Elisei, 2018, Journal of Endocrinological Investigation.

Long-term safety of orbital radiotherapy for Graves' ophthalmopathy.

M. Nardi, C. Marcocci, A. Pinchera, 2003, The Journal of clinical endocrinology and metabolism.

Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study

M. Nardi, M. Pellegrini, M. Figus, 2021, Eye and Vision.

Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.

M. Nardi, C. Marcocci, A. Pinchera, 2001, The Journal of clinical endocrinology and metabolism.

Real-time PCR provides evidence for thyrotropin receptor mRNA expression in orbital as well as in extraorbital tissues.

C. Marcocci, A. Pinchera, L. Chiovato, 2002, European journal of endocrinology.

Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy

M. Nardi, M. Mantuano, M. Figus, 2020, Journal of Endocrinological Investigation.

Altered tear composition in smokers and patients with graves ophthalmopathy.

M. Ludgate, M. Bullock, B. Mazzi, 2006, Archives of ophthalmology.

Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study

M. Nardi, P. Vitti, F. Menconi, 2018, Journal of Endocrinological Investigation.

High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.

M. Nardi, C. Marcocci, P. Vitti, 2018, Thyroid : official journal of the American Thyroid Association.

Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.

M. Nardi, C. Marcocci, P. Vitti, 2015, Thyroid : official journal of the American Thyroid Association.

Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial.

M. Nardi, C. Marcocci, A. Pinchera, 2012, The Journal of clinical endocrinology and metabolism.

Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids.

M. Nardi, C. Marcocci, A. Pinchera, 2007, The Journal of clinical endocrinology and metabolism.

Thyroglobulin in orbital tissues from patients with thyroid-associated ophthalmopathy: predominant localization in fibroadipose tissue.

A. Pinchera, L. Chiovato, S. Sellari-Franceschini, 2002, Thyroid : official journal of the American Thyroid Association.

Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy.

L. Chiovato, S. Sellari-Franceschini, F. Latrofa, 2001, Thyroid : official journal of the American Thyroid Association.

Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study.

C. Marcocci, P. Vitti, M. Brunetto, 2015, European journal of endocrinology.

Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy

L. Chiovato, P. Vitti, F. Menconi, 2018, Journal of Endocrinological Investigation.

Orbital radiotherapy for Graves' ophthalmopathy.

C. Marcocci, A. Pinchera, G. Barbesino, 2002, Thyroid : official journal of the American Thyroid Association.

Does Graves’ Orbitopathy Ever Disappear Answers to an Old Question

M. Nardi, C. Marcocci, P. Vitti, 2017, European Thyroid Journal.

Retinal, choroidal and optic disc analysis in patients with Graves’ disease with or without orbitopathy

M. Figus, G. Casini, M. Marinò, 2020, International Ophthalmology.

Soluble interleukin‐1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids

C. Marcocci, A. Pinchera, G. Barbesino, 2000, Clinical endocrinology.

VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.

M. Nardi, C. Marcocci, P. Vitti, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy

M. Nardi, P. Vitti, F. Menconi, 2015, Journal of Endocrinological Investigation.

Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy.

C. Marcocci, P. Vitti, M. Brunetto, 2015, Thyroid : official journal of the American Thyroid Association.

Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial

C. Marcocci, P. Vitti, I. Dallan, 2018, Journal of Endocrinological Investigation.

Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy

P. Vitti, M. Brunetto, F. Menconi, 2016, Journal of Endocrinological Investigation.

Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction.

M. Nardi, C. Marcocci, A. Pinchera, 2012, Thyroid : official journal of the American Thyroid Association.

Reasons for revision surgery after orbital decompression for Graves’ orbitopathy

M. Nardi, C. Marcocci, A. Pinchera, 2008, Clinical ophthalmology.

Rehabilitative orbital decompression for Graves’ orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome and patients’ satisfaction. A large retrospective study.

M. Nardi, C. Marcocci, A. Pinchera, 2012 .